Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 494

1.

Diagnostic Criteria for Oncocytic Renal Neoplasms: A Survey of Urologic Pathologists.

Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Priya Kunju L, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS.

Hum Pathol. 2017 Mar 14. pii: S0046-8177(17)30076-X. doi: 10.1016/j.humpath.2017.03.004. [Epub ahead of print]

PMID:
28315424
2.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

3.

Detecting circulating tumor DNA in renal cancer: An open challenge.

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M.

Exp Mol Pathol. 2017 Feb 22;102(2):255-261. doi: 10.1016/j.yexmp.2017.02.009. [Epub ahead of print]

PMID:
28214514
4.

Prominent oncogenic roles of EVI1 in breast carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm T, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Feb 16. pii: canres.0593.2016. doi: 10.1158/0008-5472.CAN-16-0593. [Epub ahead of print]

PMID:
28209621
5.

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.

BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

6.

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C.

Prostate. 2017 Apr;77(5):549-556. doi: 10.1002/pros.23296.

PMID:
28093792
7.

Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.

Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.

BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.

8.

VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.

Razafinjatovo CF, Stiehl D, Deininger E, Rechsteiner M, Moch H, Schraml P.

Oncotarget. 2017 Feb 7;8(6):10199-10212. doi: 10.18632/oncotarget.14372.

9.

Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers.

Hofmann AL, Behr J, Singer J, Kuipers J, Beisel C, Schraml P, Moch H, Beerenwinkel N.

BMC Bioinformatics. 2017 Jan 3;18(1):8. doi: 10.1186/s12859-016-1417-7.

10.

Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients.

Widmann R, Caduff R, Giudici L, Zhong Q, Vogetseder A, Arlettaz R, Frey B, Moch H, Bode PK.

Virchows Arch. 2017 Feb;470(2):217-223. doi: 10.1007/s00428-016-2056-0.

PMID:
27975126
11.

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients.

Lukamowicz-Rajska M, Mittmann C, Prummer M, Zhong Q, Bedke J, Hennenlotter J, Stenzl A, Mischo A, Bihr S, Schmidinger M, Vogl U, Blume I, Karlo C, Schraml P, Moch H.

Oncotarget. 2016 Nov 29;7(48):78433-78447. doi: 10.18632/oncotarget.12618.

12.

Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V.

Cancer. 2017 Jan;125(1):30-40. doi: 10.1002/cncy.21771.

PMID:
27636102
13.

Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.

Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ.

Oncotarget. 2016 Aug 25. doi: 10.18632/oncotarget.11605. [Epub ahead of print]

14.

Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types.

Beleut M, Soeldner R, Egorov M, Guenther R, Dehler S, Morys-Wortmann C, Moch H, Henco K, Schraml P.

PLoS One. 2016 Aug 18;11(8):e0161514. doi: 10.1371/journal.pone.0161514.

15.

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.

Razafinjatovo C, Bihr S, Mischo A, Vogl U, Schmidinger M, Moch H, Schraml P.

BMC Cancer. 2016 Aug 17;16:638. doi: 10.1186/s12885-016-2688-0.

16.

Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases.

Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z.

Oncoimmunology. 2016 May 5;5(6):e1153208. doi: 10.1080/2162402X.2016.1153208.

17.

Interleukin-33 in human gliomas: Expression and prognostic significance.

Gramatzki D, Frei K, Cathomas G, Moch H, Weller M, Mertz KD.

Oncol Lett. 2016 Jul;12(1):445-452.

18.

[The WHO/ISUP grading system for renal carcinoma].

Moch H.

Pathologe. 2016 Jul;37(4):355-60. doi: 10.1007/s00292-016-0171-y. German.

PMID:
27271258
19.

Accelerating the Development and Validation of New Value-Based Diagnostics by Leveraging Biobanks.

Schneider D, Riegman PH, Cronin M, Negrouk A, Moch H, Balling R, Penault-Llorca F, Zatloukal K, Horgan D.

Public Health Genomics. 2016;19(3):160-9. doi: 10.1159/000446534.

PMID:
27237867
20.

Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.

Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D.

PLoS One. 2016 May 23;11(5):e0156115. doi: 10.1371/journal.pone.0156115.

Supplemental Content

Support Center